"What we have today for
cancer drugs is a protected environment where as soon as they have an FDA
label, payers have to cover it. Period. At any price. And in that environment,
you're going to see high pricing."
— Lee Newcomer, M.D.,
principal at Lee N. Newcomer Consulting LLC, talked with AIS's RADAR on Specialty Pharmacy
about Loxo Oncology, Inc. and Bayer Corp.'s Vitrakvi, the second-ever
tissue-agnostic cancer drug. The drug costs more than $32,800 per month, but
patients who do not respond to treatment will receive refunds.
No comments:
Post a Comment